Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $27.80 Consensus PT from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned an average recommendation of “Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the last year is $27.80.

Several analysts have recently weighed in on the company. Oppenheimer reissued an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price target on shares of Catalyst Pharmaceuticals in a research note on Monday, June 3rd. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 7th.

Catalyst Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ CPRX opened at $16.58 on Wednesday. Catalyst Pharmaceuticals has a 12 month low of $11.55 and a 12 month high of $17.50. The company has a market cap of $1.96 billion, a P/E ratio of 30.70, a P/E/G ratio of 1.54 and a beta of 0.71. The business’s 50 day moving average is $15.73 and its two-hundred day moving average is $15.37.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. The company had revenue of $98.51 million for the quarter, compared to analyst estimates of $97.24 million. Sell-side analysts expect that Catalyst Pharmaceuticals will post 1.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 80,000 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $16.16, for a total value of $1,292,800.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $830,478.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 80,000 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $16.16, for a total value of $1,292,800.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $830,478.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Molly Harper sold 5,333 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $16.30, for a total value of $86,927.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,197 shares of company stock valued at $1,777,560. 11.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after acquiring an additional 860,244 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Catalyst Pharmaceuticals by 139.5% in the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after purchasing an additional 1,587,794 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Catalyst Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company’s stock valued at $43,738,000 after purchasing an additional 41,923 shares during the last quarter. Boston Partners increased its holdings in Catalyst Pharmaceuticals by 965.2% in the fourth quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock valued at $25,610,000 after purchasing an additional 1,396,930 shares during the last quarter. Finally, Opaleye Management Inc. increased its holdings in Catalyst Pharmaceuticals by 4.3% in the fourth quarter. Opaleye Management Inc. now owns 1,257,200 shares of the biopharmaceutical company’s stock valued at $21,436,000 after purchasing an additional 52,200 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.